Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study

Open access
El-Khalili, Nizar, Joyce, Mark, Atkinson, Sarah, Buynak, Robert J., Datto, Catherine, Lindgren, Petter, Eriksson, Hans · 2010 · The International Journal of Neuropsychopharmacology

Abstract

This study evaluated once-daily extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with major depressive disorder (MDD) with inadequate response to ongoing antidepressant treatment. In this 8-wk (6-wk active treatment/2-wk post-treatment drug-discontinuation/follow-up), multicentre, double-blind, placebo-controlled, Phase III study, 446 patients were randomized to quetiapine XR 150 mg/d, 300 mg/d, or placebo adjunct to ongoing antidepressant treatment. The primary endpoint was the change from randomization to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score. At week 6, MADRS total scores significantly improved with quetiapine XR 300 mg/d vs. placebo (-14.7 vs. -11.7, p<0.01). Quetiapine XR 300 mg/d showed significant improvements vs. placebo for: MADRS total score from week 1 onwards; MADRS response [(> or = 50% total score reduction) 58.9% vs. 46.2%, p<0.05] and remission [(total score < or = 8) 42.5% vs. 24.5%, p<0.01] rates; Hamilton Depression Rating Scale (HAMD) (-13.53 vs. -10.80, p<0.01) and Clinical Global Impression-Severity of illness (CGI-S) change (-1.52 vs. -1.23, p<0.05) at week 6. For quetiapine XR 150 mg/d, improvements were not significantly different vs. placebo, except for MADRS (weeks 1 and 2) and HAMD (week 6) total scores. Withdrawal rates due to adverse events (AEs) were: quetiapine XR 150 mg/d 11.5%, 300 mg/d 19.5%, and placebo 0.7%. The most common AEs (>10%) with quetiapine XR were dry mouth, somnolence, sedation, dizziness, constipation, nausea, insomnia, headache, and fatigue. In this study, quetiapine XR 300 mg/d as adjunctive therapy in patients with MDD with an inadequate response to ongoing antidepressant treatment was effective at week 6. However, the difference from placebo for quetiapine XR 150 mg/d at week 6 was not statistically significant. Both doses studied (150 and 300 mg/d) were effective at week 1 and generally well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145710000015

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 26

  1. 10.1080/13651500410005720 · DOI
  2. 10.4088/JCP.0707e17 · DOI · Paper page
  3. Weisler, 2009, CNS Spectrums, 14, 299, 10.1017/S1092852900020307 · DOI
  4. Trivedi, 2006, Journal of Clinical Psychiatry, 67, 27
  5. 10.1185/030079904125004510 · DOI
  6. 10.4088/JCP.v68n0604 · DOI · Paper page
  7. 10.1080/15622970701227829 · DOI · Paper page
  8. 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
  9. 10.1192/bjp.154.5.672 · DOI · Paper page
  10. 10.4088/JCP.v65n0714 · DOI
  11. 10.1016/S0140-6736(07)61238-0 · DOI · Paper page
  12. 10.1176/appi.ajp.164.7.1035 · doi:10.1176/appi.ajp.164.7.1035 · Paper page
  13. 10.1016/S0924-977X(08)70352-3 · doi:10.1016/s0924-977x(08)70352-3
  14. Guy, 1970, Manual for the ECDEU Assessment Battery, 1
  15. 10.1016/S0149-2918(03)80220-5 · DOI · Paper page
  16. Kennedy, 2001, Canadian Journal of Psychiatry, 46, 38S, 10.1177/070674372001460101004 · DOI · Paper page
  17. Katila, 2008, International Journal of Psychiatry in Clinical Practice, 12, 337
  18. 10.1038/sj.npp.1301646 · DOI · Paper page
  19. 10.1093/biomet/75.2.383 · DOI · Paper page
  20. Hirschfeld, 2002, Journal of Clinical Psychiatry, 63, 826, 10.4088/JCP.v63n0913 · DOI · Paper page
  21. 10.1016/j.eurpsy.2008.01.325 · DOI
  22. Endicott, 1993, Psychopharmacology Bulletin, 29, 321
  23. El-Khalili, 2009, World Journal of Biological Psychiatry, 10, 230
  24. 10.1016/S0924-977X(08)70540-6 · doi:10.1016/s0924-977x(08)70540-6
  25. 10.4088/JCP.08m04592 · DOI
  26. Casey, 2006, CNS Spectrums, 11, 25, 10.1017/S1092852900026651 · DOI

Cited by

See all 185

Metadata

Authors
El-Khalili, N., Joyce, M., Atkinson, S., Buynak, R. J., Datto, C., Lindgren, P., & Eriksson, H.
Venue
The International Journal of Neuropsychopharmacology
Published
2010-02-23
Volume
13
Issue
07
Pages
917-932
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2078154303
Cited by
185
References
15
FWCI
14.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1017/s1461145710000015
The paper
El-Khalili, N., Joyce, M., Atkinson, S., Buynak, R. J., Datto, C., Lindgren, P., & Eriksson, H. (2010). Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145710000015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.